Researchers evaluated a “watch and wait” strategy that includes chemotherapy and radiation, but not surgery, in carefully selected patients with rectal cancer.
The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of < 50%.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA